Pharmaceutical Drugs

An Innovative Policy in the Law of Innovation: So Why the Outcry?

In January 2006, the Patent Office of Chennai rejected the patent application by Novartis for patent of the drug Gleevec (chemically known as imatinib mesylate). Since then till date, the Novartis saga has prompted numerous headlines and scores of commentaries. What is so unique about the entire controversy? After all, aren’t patent applications rejected by […]

Patent on Improvements- Did the Novartis Case Really Solve the Issue?

India, which followed the approach of process patenting to pharmaceuticals switched over to product patenting by way of an amendment in 2005 in order to be in consonance with the TRIPs agreement. However, India also used the flexibility offered by the WTO rules, which while setting a minimum standard for patent protection, restrained from defining […]